Journal article
Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer
H Fettke, EM Kwan, P Bukczynska, JA Steen, M Docanto, N Ng, P Parente, A Mant, S Foroughi, C Pezaro, C Hauser, T Nguyen-Dumont, MC Southey, AA Azad
Prostate | WILEY | Published : 2021
DOI: 10.1002/pros.24194
Abstract
Background: The androgen receptor (AR) pathway-associated gene nuclear receptor coactivator 2 (NCOA2) has an established oncogenic role in early prostate cancer and likewise is a driver of metastatic disease and castration-resistant prostate cancer. However, its significance as a biomarker in metastatic castration-resistant prostate cancer (mCRPC), both alone and in conjunction with co-occurring AR alterations using a liquid biopsy approach has not been investigated. Methods: Ninety-one patients were included in this study, (n = 68 receiving an androgen receptor pathway inhibitor and n = 23 receiving taxane chemotherapy). Up to 30 ml of peripheral blood was collected before commencing treatm..
View full abstractGrants
Awarded by National Breast Cancer Foundation
Awarded by Victorian Cancer Agency
Awarded by National Health and Medical Research Council
Funding Acknowledgements
Monash University, Grant/Award Numbers: Postgraduate Publications award -Edmond M. Kwan, Postgraduate publications award -Heidi Fettke; National Breast Cancer Foundation, Grant/Award Number: CECF-17-001 -Tu Nguyen-Dumont; Victorian Cancer Agency, Grant/Award Number: CRF14009 -Arun A. Azad; Astellas Pharma, Grant/Award Number: Investigator-initiated grant -Arun Azad; Australian Government, Grant/Award Number: Research Training Program Scholarship -Heidi Fettke; National Health and Medical Research Council, Grant/Award Numbers: APP1155163 -Melissa C. Southey, GNT1098647 -Arun A. Azad, Postgraduate scholarship -Edmond M. Kwan